Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shionogi & Co ( (JP:4507) ).
Shionogi has raised its year-end dividend forecast for the fiscal year ending March 31, 2026 to 38 yen per share, lifting the annual payout to 71 yen and marking a 10-yen increase from the previous year. The move reflects solid earnings under its STS2030 plan and extends its streak of annual dividend hikes to 14 years, underscoring a commitment to shareholder returns based on DOE, EPS, and ROE metrics.
Management attributes the higher dividend capacity to strong growth in its HIV franchise, where long-acting injectables Cabenuva and Apretude continue to gain traction, and to progress on a third-generation integrase inhibitor. Recent acquisitions, including JT Group’s pharmaceutical business and the edaravone franchise, along with robust sales of antivirals Xocova and Xofluza and steady overseas revenue from cefiderocol, have strengthened Shionogi’s earnings base and long-term growth platform.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen3300.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company focused on prescription drugs, with particular strengths in infectious diseases and HIV treatments. The company is expanding its portfolio into quality-of-life and rare disease areas, while also reinforcing overseas operations, especially in the United States, through targeted acquisitions and partnerships.
YTD Price Performance: 10.51%
Average Trading Volume: 2,807,383
Technical Sentiment Signal: Buy
Current Market Cap: Yen2735.3B
For an in-depth examination of 4507 stock, go to TipRanks’ Overview page.